Zebrafish | Jotup

Black Soldier Fly Market is Expected to Reach $3.96 Billion by 2033 - Exclusive Report by Meticulous Research®

Retrieved on:

木曜日, 5月 2, 2024

USD, BSF, Prince, Protein, Poultry, Risk, Aquaculture, Pet food, Research, Animal feed, Zebrafish, Cocoon, BSFL, Attention, Human, Diet, Salmon, Livestock, Food, Nutrient, BNP Paribas, InnovaFeed, Good, Meat, Government, Growth

In addition, expansions in developed and emerging economies provide significant opportunities for the growth of the black soldier fly market.

Key Points:

In addition, expansions in developed and emerging economies provide significant opportunities for the growth of the black soldier fly market.
In 2024, the aquafeed segment is expected to account for the largest share of 44% of the black soldier fly market.
In terms of value, in 2024, Europe is expected to account for the largest share of 55% of the black soldier fly market.
Moreover, North America black soldier fly market is expected to witness the highest CAGR of 34.4% during the forecast period.

Black Soldier Fly Market is Expected to Reach $3.96 Billion by 2033 - Exclusive Report by Meticulous Research®

Retrieved on:

木曜日, 5月 2, 2024

In addition, expansions in developed and emerging economies provide significant opportunities for the growth of the black soldier fly market.

Key Points:

In addition, expansions in developed and emerging economies provide significant opportunities for the growth of the black soldier fly market.
In 2024, the aquafeed segment is expected to account for the largest share of 44% of the black soldier fly market.
In terms of value, in 2024, Europe is expected to account for the largest share of 55% of the black soldier fly market.
Moreover, North America black soldier fly market is expected to witness the highest CAGR of 34.4% during the forecast period.

H. Joseph Yost, Ph.D. Appointed Senior Vice Provost for Research

Retrieved on:

火曜日, 4月 23, 2024

Washington, D. C., April 23, 2024 (GLOBE NEWSWIRE) -- A world-renowned scientist and researcher, H. Joseph Yost, Ph.D. has been appointed to the newly created position of senior vice provost for research at The Catholic University of America, where he will lead efforts to expand the University’s research capabilities and build upon the rich research tradition of the 137-year-old institution.

Key Points:

Washington, D. C., April 23, 2024 (GLOBE NEWSWIRE) -- A world-renowned scientist and researcher, H. Joseph Yost, Ph.D. has been appointed to the newly created position of senior vice provost for research at The Catholic University of America, where he will lead efforts to expand the University’s research capabilities and build upon the rich research tradition of the 137-year-old institution.
Yost is coming to Catholic University from the University of Utah School of Medicine bringing more than three decades of teaching and research experience.
He is currently the Richard L. Stimson presidential endowed chair, vice chairman for basic science research in the department of pediatrics, and professor of neurobiology and anatomy.
“I am honored and deeply grateful for the opportunity to help build The Catholic University of America to a top tier research university.

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Retrieved on:

火曜日, 4月 9, 2024

Toxicity, PMN, MSA, Bioorganic chemistry, ALS, Multiple system atrophy, Zebrafish, SOD1, Neuroscience, Journal, Brain cell, TAR, Protein, Biochemistry, PROMIS, Antibody, Therapy, Vaccine

ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.

Key Points:

ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.
ALS is a fatal neurodegenerative disease of motor neurons.
“Publication of these data underscores the connection of misfolded proteins and ALS and supports targeting our TDP-43-specific epitope with PMN267 as a potential therapeutic approach,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
“PMN267 is advancing through preclinical development and is showing promise as a potential treatment for ALS.

Overeating and starving both damage the liver: Cavefish provide new insight into fatty liver disease

Retrieved on:

木曜日, 3月 14, 2024

KANSAS CITY, Mo., March 14, 2024 /PRNewswire/ -- Fatty liver, which can lead to liver damage and disease, can occur from both overeating and starvation. Now, new research shows how naturally starvation-resistant cavefish, unlike other animals, are able to protect their liver and remain healthy. The findings have implications for understanding and potentially addressing liver conditions in humans.

Key Points:

KANSAS CITY, Mo., March 14, 2024 /PRNewswire/ -- Fatty liver, which can lead to liver damage and disease, can occur from both overeating and starvation.
Now, new research shows how naturally starvation-resistant cavefish, unlike other animals, are able to protect their liver and remain healthy.
"We have discovered for the first time an organism – cavefish—that can avoid fatty liver under starvation conditions," said Cobham.
"Fatty liver can result in complications like liver cirrhosis and liver failure.

Associate Professor Ron Korstanje, Ph.D., of The Jackson Laboratory named Evnin Family Chair

Retrieved on:

金曜日, 3月 1, 2024

BAR HARBOR, Maine, March 1, 2024 /PRNewswire/ -- Associate Professor Ron Korstanje, Ph.D., has been named the Evnin Family Chair at The Jackson Laboratory. An expert in the genetics of kidney function and disease, Korstanje's appointment marks a new chapter in his 20 years of service to JAX's mission.

Key Points:

BAR HARBOR, Maine, March 1, 2024 /PRNewswire/ -- Associate Professor Ron Korstanje, Ph.D., has been named the Evnin Family Chair at The Jackson Laboratory.
"His appointment as the Evnin Family Chair bolsters our commitment to understanding the most complex health challenges of our time.
I'm grateful to him, and to the Evnin family for their support in helping us recruit and retain top scientists."
After returning to JAX in 2007 as a research scientist in Paigen's laboratory, he advanced to the rank of associate professor in 2019.

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on:

木曜日, 2月 15, 2024

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.

Key Points:

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.
The TaRGET trial is a critical first step in evaluating this potential."
This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD).
An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD.

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on:

木曜日, 2月 15, 2024

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.

Key Points:

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.
The TaRGET trial is a critical first step in evaluating this potential."
This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD).
An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD.

InVivo Biosystems Secures New Investment to Accelerate CRISPR Innovation

Retrieved on:

水曜日, 1月 3, 2024

EUGENE, Ore., Jan. 3, 2024 /PRNewswire-PRWeb/ -- InVivo Biosystems, experts in CRISPR-edited animals for biomedical discovery, today announced $3M in new investment in furtherance of the company's mission to revolutionize drug discovery leveraging its extensive intellectual property in genetically modified organisms. Rogue Venture Partners led the new investment round that included Portland Seed Fund, ONAMI, and Launch Oregon to fund further CRISPR commercialization.

Key Points:

Rogue Venture Partners led the new investment round that included Portland Seed Fund, ONAMI, and Launch Oregon to fund further CRISPR commercialization.
"The new investment in our corporate vision at a time when CRISPR's capabilities to transform therapeutic outcomes is worldwide news, will fuel existing innovation initiatives and breakthrough capabilities," said Matt Beaudet, Chief Executive Officer, InVivo Biosystems.
With its CRISPR genome editing platform, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models for preclinical studies and drug discovery.
In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies to help accelerate decision-making in the early-stage development of new compounds.

Cells Move in Groups Differently Than They Do When Alone

Retrieved on:

水曜日, 12月 13, 2023

NYU Langone Health, National Institutes of Health, Cell biology, Tissue, Protein, Multimedia, Transforming protein RhoA, Zebrafish, Movement, Biology, Bacteria, NYU, Cancer, Human, Doctor of Philosophy, Current Biology, Cell, American Heart Association, Mobile phone

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- A protein that helps generate the force needed for single cells to move works differently in cells moving in groups, a new study shows.

Key Points:

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- A protein that helps generate the force needed for single cells to move works differently in cells moving in groups, a new study shows.
Zebrafish are a major model in the study of development because they are transparent and share cellular mechanisms with humans.
The current study found that the cells in the primordium instead activate RhoA in pulses in the front of the cells where it does two jobs.
"The machinery suggests that the movement of single cells and groups of cells is similar, but that RhoA contributes to that machinery differently in each case.